Nonmelanoma skin cancer (NMSC) is a slow-growing disease that makes up the majority of all newly diagnosed skin cancer cases.
Many options to treat NMSC exist, including surgery, radiation therapy, photodynamic therapy and drug therapies. One type of NMSC, Merkel cell carcinoma (MCC), can be treated with an immunotherapy strategy known as a checkpoint inhibitor. MCC is a fast-growing cancer located on the top layer of the skin near nerve endings. Checkpoint inhibitors are drugs that block specific proteins and receptors from triggering a slowdown of the immune system.